Abigail R. Barber

Dec 17, 2023 | biorxiv.org | Hannah E Greenwood |Richard Edwards |Will Tyrrell |Abigail R. Barber

AbstractMutations in the NRF2-KEAP1 pathway are common in non-small cell lung cancer (NSCLC) and confer broad-spectrum therapeutic resistance, leading to poor outcomes. The cystine/glutamate antiporter, system xc−, is one of the >200 cytoprotective proteins controlled by NRF2, which can be non-invasively imaged by (S)-4-(3-18F-fluoropropyl)-ʟ-glutamate ([18F]FSPG) positron emission tomography (PET).